Authors
Patton, E. E.Mueller, K. L.
Adams, D. J.
Anandasabapathy, N.
Aplin, A. E.
Bertolotto, C.
Bosenberg, M.
Ceol, C. J.
Chi, P.
Herlyn, M.
Holmen, S. L.
Karreth, F. A.
Kaufman, C. K.
Khan, S.
Kobold, S.
Leucci, E.
Levy, C.
Lombard, D. B.
Lund, A. W.
Marie, K. L.
Marine, J. C.
Marais, Richard
McMahon, M.
Robles-Espinoza, C. D.
Ronai, Z. A.
Samuels, Y.
Soengas, M. S.
Villanueva, J.
Weeraratna, A. T.
White, R. M.
Yeh, I.
Zhu, J.
Zon, L. I.
Hurlbert, M. S.
Merlino, G.
Affiliation
MRC Human Genetics Unit and Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XUIssue Date
2021
Metadata
Show full item recordAbstract
There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.Citation
Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, et al. Melanoma models for the next generation of therapies. Cancer Cell. 2021.Journal
Cancer CellDOI
10.1016/j.ccell.2021.01.011PubMed ID
33545064Additional Links
https://dx.doi.org/10.1016/j.ccell.2021.01.011Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ccell.2021.01.011